Teva receives FDA approval for biosimilar

18.42 update

Teva Pharmaceutical Industries Ltd. (NYSE: Tifa;; level: Tiva) I mentioned that the FDA has agreed to the biological treatment with which it develops with Alvotech. The Food and Drug Administration (FDA) has ruled that SERARSDI, which was launched by the companies, is replaced with Stelara drugs with biological brands and can be used in all indigenous product indicators.

This means that the American health system can replace the vital brands of brands and alvotech. The drug is designed to treat psoriasis arthritis for adults, children and plaque psoriasis, as well as Crohn’s disease, and ulcerative colitis. The brand version is sold in large quantities by Johnson & Johnson, which shops for the drug, and has reported sales of about $ 10.4 billion in 2024, a decrease of $ 10.9 billion in 2023.

TEVA SVP Us Biosimilars Thomas Rainyy said: “The last TEVA launch of two Biosimilars – Serarsdi and EPYSQLI – along with a rich pipeline of assets expected to be launched over the next few years, the TEVA mode to create a strong leadership position in the growing landscape of biology and leadership in the field Strategy.

The price of the TEVA shares has recently increased due to positive expectations about the financial results in the first quarter of the Israeli pharmaceutical company, which will be published on Wednesday. Tiva, led by CEO Richard Francis, is currently being traded in Wall Street with a maximum of $ 18.6 billion.

It was published by Globes, Israel Business News – En.globes.co.il – on May 5, 2025.

© Copy Publish Publisher Itonut (1983) Ltd. , 2025.